Comparative Device Assessments Humalog KwikPen Compared With Vial and Syringe and FlexPen

PurposeThe purpose of this study was to compare pen device-naive patients’ preferences for Humalog® KwikPen™ (insulin lispro injection) (Eli Lilly and Company, Indianapolis, IN) to use of a vial and syringe and FlexPen® (insulin aspart injection) (Novo Nordisk A/S, Bagsvaerd, Denmark).MethodsThis open-label, randomized, crossover 1-day study tested the hypotheses that KwikPen was preferred to vial and syringe, and if this was found to be a significant preference, that KwikPen was preferred to FlexPen. Accuracy of doses prepared, ease of use via insulin device assessment battery, and preference via insulin device preference battery were administered following each pen evaluation, and a final preference question administered following the evaluation of both pens. Clinical measures were not included as subjects injected into an appliance to simulate the injection experience. Primary outcome variables were evaluated by Question 13 of the insulin device preference battery and the final preference question.Resu...